ArticleNuclear medicine and molecular imaging2014
The Effect of SSRIs on the Binding of (18)F-FP-CIT in Parkinson Patients: A Retrospective Case Control Study.
Article in Nuclear medicine and molecular imaging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [European journal of nuclear medicine and molecular imaging · 2023Pooled it
- Preclinical evaluation of [EJNMMI research · 2024Article
- Imaging Procedure and Clinical Studies of [Nuclear medicine and molecular imaging · 2024Review
- Diagnostic accuracy ofScientific reports · 2023Article
- Usefulness of PET With [Frontiers in neurology · 2020Article
- Ventral striatal dopamine transporter availability is associated with lower trait motor impulsivity in healthy adults.Translational psychiatry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose(18)F-FP-CIT [(18)F-fluorinated N-3-fluoropropyl-2-beta-carboxymethoxy-3-beta-(4-iodophenyl) nortropane] is useful for detecting striatal dopamine transporter (DAT). Since FP-CIT shows relatively high affinities for DAT and serotonin transporter (SERT), its binding can be influenced by selective serotonin reuptake inhibitors (SSRIs). We aimed to evaluate the effect of SSRIs on the binding of (18)F-FP-CIT.
methodsIn our (18)F-FP-CIT positron emission tomography (PET) data pool, images of 24 drug-naive Parkinson's disease (PD) patients (62.6 ± 10.6 years), 111 PD patients taking SSRIs [escitalopram (n = 19) and fluvoxamine (n = 20)] or clonazepam (n = 72), and 10 normal people were reviewed. PET images acquired 3 h after (18)F-FP-CIT injection were analyzed by an automated method using a predefined volume of interest (VOI) set of the striatum (ST), occipital cortex (OC), raphe nuclei (RN), and cerebellar cortex (CB). The uptake ratios (URs) of each VOI to the CB were compared among the groups.
resultsThe ST/CB URs of all PD groups were significantly lower than that of normal group. When adjusted for drug severity, ST/CB URs were higher in drug-naive group but had no difference among antidepressant groups. Whereas OC/CB URs were not different among groups (p > 0.05), RN/CB URs were significantly lower in SSRI groups than in non-SSRI groups (p < 0.001) and showed similar results when adjusted for disease severity.
conclusionsPD patients taking SSRIs showed significantly decreased URs in the RN but not the OC. When adjusted for Hoehn and Yar (HY) score, ST URs were not different among antidepressant groups. This result suggests that the OC may be used as a reference region for the quantification of DAT binding in (18)F-FP-CIT PET images of PD patients taking SSRIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.